Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide

BACKGROUND: Tenofovir alafenamide (TAF) is a new formulation of tenofovir disoproxil fumarate (TDF) that was approved in 2015. While clinical trial evidence suggests that TAF has more favorable outcomes related to kidney injury and loss of bone mineral density, TAF also leads to higher lipid levels...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Manag Care Spec Pharm
Hlavní autoři: Hung, Anna, Sinclair, Matthew, Hemmersbach-Miller, Marion, Edmonston, Daniel, Wyatt, Christina
Médium: Artigo
Jazyk:Inglês
Vydáno: Academy of Managed Care Pharmacy 2020
Témata:
Research Brief
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8098116/
https://ncbi.nlm.nih.gov/pubmed/33251997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2020.26.12.1582
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky